Abstract
Every USA wave, including this latest Spring 2022 Resurgence has been successfully modeled using:
with N (t) being the total number of new CoVID-19 cases above a prior baseline, and tR setting the pandemic wave doubling time tdbl = tR (In 2). The parameters {αS ; δo} measure mitigation efforts among the uninfected population. Here, {αS > 0} is associated with Social Distancing and vaccinations ; while {δo > 0} is associated with mask-wearing, which results in faster 
post-peak drop-offs. The predicted pandemic wave end is when the calculated N (t) stops increasing.
The USA Winter 2021 Resurgence resulted in fewer Omicron CoVID-19 cases than calculated in our prior medrxiv.org preprint*, due to an increased δo component, which gives ∼3/11/22 as the predicted wave end. A relatively quiet CoVID-19 period ensued until ∼4/16/22, when a new Omicron variant caused the present Spring 2022 CoVID-19 resurgence.
The recent CoVID-19 waves have decreasing tR values, with the Spring 2022 tR ≈ 3.55 days (tdbl ≈ 2.46 days) value being the shortest since the initial 2020 pandemic, indicating increasingly infectious variants. The Winter 2021 and the present Spring 2022 CoVID-19 resurgences have identical αS ≈ 0.043 / day values, but the δo > 0 mask-wearing parameter decreased from δo ≈ 3. 14 × 10−3/ day to δo ≈ 1. 145 × 10−3/ day, giving the Spring 2022 wave a longer tail, and an expected end date of 8/25/22, with these wave totals:
When all the USA CoVID-19 waves are combined, it gives:
assuming no future CoVID-19 Resurgences (with 5 Figures).
*(10.1101_2022.02.04.22270491)
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All CoVID-19 data used here came from the open-source bing.com CoVID-Tracker⁹ database: www.bing.com/covid/local/unitedstates?form=COVD07
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
